146 related articles for article (PubMed ID: 18759130)
1. Signal transduction molecules in gliomas of all grades.
Ermoian RP; Kaprealian T; Lamborn KR; Yang X; Jelluma N; Arvold ND; Zeidman R; Berger MS; Stokoe D; Haas-Kogan DA
J Neurooncol; 2009 Jan; 91(1):19-26. PubMed ID: 18759130
[TBL] [Abstract][Full Text] [Related]
2. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
[TBL] [Abstract][Full Text] [Related]
3. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.
McBride SM; Perez DA; Polley MY; Vandenberg SR; Smith JS; Zheng S; Lamborn KR; Wiencke JK; Chang SM; Prados MD; Berger MS; Stokoe D; Haas-Kogan DA
J Neurooncol; 2010 Mar; 97(1):33-40. PubMed ID: 19705067
[TBL] [Abstract][Full Text] [Related]
4. EGFR signals to mTOR through PKC and independently of Akt in glioma.
Fan QW; Cheng C; Knight ZA; Haas-Kogan D; Stokoe D; James CD; McCormick F; Shokat KM; Weiss WA
Sci Signal; 2009 Jan; 2(55):ra4. PubMed ID: 19176518
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of RSK1 characterizes high-grade gliomas with immune infiltration.
M Hajj GN; da Silva FF; de Bellis B; Lupinacci FCS; Bellato HM; Cruz JR; Segundo CNC; Faquini IV; Torres LC; Sanematsu PI; Begnami MD; Martins VR; Roffé M
Mol Oncol; 2020 Jan; 14(1):159-179. PubMed ID: 31701625
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
[TBL] [Abstract][Full Text] [Related]
7. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
8. Akt-mTOR signaling is involved in Notch-1-mediated glioma cell survival and proliferation.
Zhao N; Guo Y; Zhang M; Lin L; Zheng Z
Oncol Rep; 2010 May; 23(5):1443-7. PubMed ID: 20372862
[TBL] [Abstract][Full Text] [Related]
9. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
Nakamura JL; Karlsson A; Arvold ND; Gottschalk AR; Pieper RO; Stokoe D; Haas-Kogan DA
J Neurooncol; 2005 Feb; 71(3):215-22. PubMed ID: 15735908
[TBL] [Abstract][Full Text] [Related]
10. mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma.
Annovazzi L; Mellai M; Caldera V; Valente G; Tessitore L; Schiffer D
Anticancer Res; 2009 Aug; 29(8):3087-94. PubMed ID: 19661320
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis.
Yang J; Liao D; Wang Z; Liu F; Wu G
J Surg Res; 2011 Jun; 168(1):97-102. PubMed ID: 20036387
[TBL] [Abstract][Full Text] [Related]
12. Co-expression modules of NF1, PTEN and sprouty enable distinction of adult diffuse gliomas according to pathway activities of receptor tyrosine kinases.
Zhang W; Lv Y; Xue Y; Wu C; Yao K; Zhang C; Jin Q; Huang R; Li J; Sun Y; Su X; Jiang T; Fan X
Oncotarget; 2016 Sep; 7(37):59098-59114. PubMed ID: 27385209
[TBL] [Abstract][Full Text] [Related]
13. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
Wahl M; Chang SM; Phillips JJ; Molinaro AM; Costello JF; Mazor T; Alexandrescu S; Lupo JM; Nelson SJ; Berger M; Prados M; Taylor JW; Butowski N; Clarke JL; Haas-Kogan D
Cancer; 2017 Dec; 123(23):4631-4639. PubMed ID: 28759109
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas.
Liu M; Lin Y; Zhang XC; Tan YH; Yao YL; Tan J; Zhang X; Cui YH; Liu X; Wang Y; Bian XW
Lab Invest; 2017 Nov; 97(11):1354-1363. PubMed ID: 28759011
[TBL] [Abstract][Full Text] [Related]
15. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
Dworakowska D; Wlodek E; Leontiou CA; Igreja S; Cakir M; Teng M; Prodromou N; Góth MI; Grozinsky-Glasberg S; Gueorguiev M; Kola B; Korbonits M; Grossman AB
Endocr Relat Cancer; 2009 Dec; 16(4):1329-38. PubMed ID: 19620247
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
17. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH
Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275
[TBL] [Abstract][Full Text] [Related]
19. miR-132-3p boosts caveolae-mediated transcellular transport in glioma endothelial cells by targeting PTEN/PI3K/PKB/Src/Cav-1 signaling pathway.
Gu Y; Cai R; Zhang C; Xue Y; Pan Y; Wang J; Zhang Z
FASEB J; 2019 Jan; 33(1):441-454. PubMed ID: 30024792
[TBL] [Abstract][Full Text] [Related]
20. KIF3C is associated with favorable prognosis in glioma patients and may be regulated by PI3K/AKT/mTOR pathway.
Gao Y; Li L; Zheng H; Zhou C; Chen X; Hao B; Cao Y
J Neurooncol; 2020 Feb; 146(3):513-521. PubMed ID: 32020481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]